“Development And Assessment Of Aspirin Emulgel For Ischemic Stroke Management”

Abstract

The aim of present work is to develop a topical emulgel of Ischemic Stroke, which would effectively deliver the drug with maximum bioavailability in less time and site specific drug delivery. Ischemic Stroke may cause damage to the vulnerable areas of cerebellum of brain. Due to the damage in these areas various significant functions of brain are affected. Ischemic stroke arises due to complete interruption of blood supply to neural tissue cause Hypoxia. Major Risk factor of Ischemia is Hypotension, Hyperlipidemia, and other cardiovascular diseases.  The major objective behind this formulation is to deliver the Hydrophobic drug (Aspirin; easily available) and increases the Absorption of Aspirin through human skin.  Aspirin is a non-steroidal anti-inflammation drug (NSAID). It widely uses as analgesic, anti-inflammatory, antipyretic and an inhibitor of platelet aggregation. Emulgel is better vehicle for Hydrophobic drug. Emulgel provide faster drug release than conventional oral dosage form and bypass the First Pass metabolism. All prepared Emulgel were evaluated for their physical appearance, pH determination, viscosity, spreadibilty and Stability test. In Vitro Studies demonstrated Sustained Drug Release and promoted therapeutic efficacy of Aspirin potential for Transdermal.Drug Delivery. Overall, The Developed Aspirin Emulgel presents a promising alternative for the Treatment of Ischemic stroke.